PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. (Q44846498)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

2

Yasushi Yatabe

1 reference

http://europepmc.org/abstract/MED/17409929

6 December 2017

author name string

Hideki Endoh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Takayuki Kosaka

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Hiroyuki Kuwano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Tetsuya Mitsudomi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Yasushi Yatabe

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thoracic Oncology

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

629-634

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Predictors of the response to gefitinib in refractory non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Signal transduction through MAP kinase cascades

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

PI3K: downstream AKTion blocks apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Mutation of the PIK3CA gene in ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930374-9

7 January 2021

10.1016/S1556-0864(15)30374-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409929%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference